¸»±â ½ÅºÎÀüÁõÀ¸·Î Åõ¼®À» ¹Þ´Â ȯÀÚ¿¡¼­ ¹ß»ýÇÑ ½ÅÁ¾±«ÀÇ ÀÓ»óÀû Ư¡
Renal masses in end-stage renal disease patients on dialysis

´ëÇѳ»°úÇÐȸÁö 2010³â 79±Ç 3È£ p.263 ~ p.270

À̹ÌÁ¤(Lee Mi-Jung) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
½Åµ¿È£(Shin Dong-Ho) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±èÇö¹Î(Kim Hyun-Min) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¹ÚÇö¼º(Park Hyun-Sung) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¹ÚÁ¤Å¹(Park Jung-Tak) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÀåÅÂÀÍ(Chang Tae-Ik) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
À¯ÅÂÇö(Yoo Tae-Hyun) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
°­½Å¿í(Kang Shin-Wook) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÃÖ±ÔÇå(Choi Kyu-Hun) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç

Abstract

¸ñÀû: ¸»±â ½ÅºÎÀüÁõÀ¸·Î Ç÷¾× Åõ¼®À̳ª º¹¸· Åõ¼®À» ¹Þ°í Àִ ȯÀÚ¿¡¼­ ¾Ç¼º Á¾¾ç, ƯÈ÷ ½Å¼¼Æ÷¾ÏÀÇ ¹ß»ý ºóµµ´Â Á¤»óÀο¡ ºñÇØ ³ôÀº °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. ±×·¯³ª ±¹³»ÀÇ ¸»±â ½ÅºÎÀüÁõ ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ ½Å¼¼Æ÷¾ÏÀÇ ÀÓ»óÀû Ư¼º¿¡ °üÇÑ ¿¬±¸´Â ¹Ì¹ÌÇÑ ½ÇÁ¤À̸ç, ½Å¼¼Æ÷¾Ï ÀÌ¿ÜÀÇ ¾ç¼º ½ÅÁ¾±«¿¡ ´ëÇÑ ¿¬±¸´Â º¸°íµÈ ¹Ù°¡ ¾ø´Ù. ÀÌ¿¡ º» ¿¬±¸¿¡¼­´Â ¸»±â ½ÅºÎÀüÁõÀ¸·Î Åõ¼®À» ¹Þ°í Àִ ȯÀÚ¿¡¼­ ¹ß»ýÇÑ ½ÅÁ¾±«ÀÇ ÀÓ»óÀû Ư¼ºÀ» ±Ô¸íÇÏ°íÀÚ ÇÏ¿´´Ù.

¹æ¹ý: 1995³â 1¿ùºÎÅÍ 2009³â 12¿ù±îÁö ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¼¼ºê¶õ½º º´¿ø¿¡¼­ ¸»±â ½ÅºÎÀüÁõÀ¸·Î Åõ¼®À» ¹Þ°í Àִ ȯÀÚ¿¡¼­ º¹ºÎ ÃÊÀ½ÆÄ ¶Ç´Â º¹ºÎ Àü»êÈ­´ÜÃþÃÔ¿µÀ» ÅëÇØ ½ÅÁ¾±«°¡ ¹ß°ßµÇ¾î Àü ȤÀº ºÎºÐ ½ÅÀûÃâ¼úÀ» ½ÃÇà¹ÞÀº 186¸í Áß, Åõ¼® Àü¿¡ ½ÅÁ¾±«°¡ ¹ß°ßµÇ¾ú°Å³ª ½ÅÀå À̽ÄÀ» ¹ÞÀº ȯÀÚ¸¦ Á¦¿ÜÇÑ ÃÑ 38¸íÀÇ È¯ÀÚ¸¦ ´ë»óÀ¸·Î ÀÓ»óÀû Ư¼º°ú ½ÅÁ¾±«ÀÇ Á¶Á÷ÇÐ ¼Ò°ßÀ» ÈÄÇâÀûÀ¸·Î ºÐ¼®ÇÏ¿´´Ù.

°á°ú: ´ë»ó ȯÀÚÀÇ Æò±Õ ¿¬·ÉÀº 48.3¡¾13.2¼¼¿´°í, ³²ÀÚ°¡ 21¸í, ¿©ÀÚ°¡ 17¸íÀ̾ú´Ù. ¿øÀÎ ½ÅÁúȯÀ¸·Î´Â ¸¸¼º »ç±¸Ã¼½Å¿°°ú °íÇ÷¾ÐÀÌ °¢°¢ 13¸í(34.2%)À¸·Î °¡Àå ÈçÇß°í, ¿ª·ù¼º½ÅÁúȯÀÌ 5¸í(13.2%), »ó¿°»öü ¿ì¼º ´Ù³¶½ÅÀÌ 4¸í(10.5%)À̾ú´Ù. Ç÷¾× Åõ¼® ȯÀÚ°¡ 20¸í(52.6%), º¹¸· Åõ¼® ȯÀÚ°¡ 18¸í(47.4%)À̾ú°í, Æò±Õ Åõ¼® ±â°£Àº 106.4¡¾62.5°³¿ùÀ̾ú´Ù. ½ÅÁ¾±«´Â ´ëºÎºÐ(36¿¹, 91.3%) ÇÑÂÊ ½ÅÀå¿¡ ±¹ÇѵǾî ÀÖ¾úÀ¸³ª, 2¿¹(8.7%)¿¡¼­´Â ¾çÂÊ ½ÅÀå ¸ðµÎ¿¡¼­ ¹ß°ßµÇ¾ú´Ù. 28¿¹(73.7%)´Â ´ÜÀÏ º´º¯À̾úÀ¸³ª, ´Ù¼öÀÇ º´º¯µµ 8¿¹(26.3%)¿¡¼­ °üÂûµÇ¾ú´Ù. Á¾±«ÀÇ Å©±â´Â Æò±Õ 3.4¡¾2.3 cm¿´´Ù. »ó ¿°»öü ¿ì¼º ´Ù³¶½ÅÀ» Á¦¿ÜÇÏ°íµµ 23¿¹(67.6%)ÀÇ È¯ÀÚ¿¡¼­ ´Ù¼öÀÇ ÈÄõ¼º ³¶Á¾ÀÌ °üÂûµÇ¾ú´Ù. Á¾±«ÀÇ Á¶Á÷ÇÐÀû °Ë»ç»ó 23¿¹(60.5%)¿¡¼­ ¾Ç¼º Á¾¾çÀÌ °üÂûµÇ¾ú´Âµ¥, ÀÌ Áß 21¿¹(91.3%)´Â ½Å¼¼Æ÷¾ÏÀ̾ú°í, Á¶Á÷ÇÐÀû ÇüÅ´ Åõ¸í ¼¼Æ÷ÇüÀÌ 16¿¹(76.2%)·Î °¡Àå ÈçÇÏ¿´°í, À¯µÎ»óÇüÀÌ 3¿¹(14.3%), ±×¸®°í Åõ¸í ¼¼Æ÷Çü°ú À¯µÎ»óÇüÀÌ È¥ÇÕµÈ °æ¿ì¿Í ´Ù¹æ ³¶¼ºÇüÀÌ °¢°¢ 1¿¹(4.7%)¿´´Ù. ¹Ý¸é, 15¿¹(39.5%)¿¡¼­´Â ¾ç¼º Á¾¾çÀÌ È®ÀεǾú´Âµ¥, Ç÷Á¾ÀÌ 6¿¹(40.0%), ³ó¾çÀÌ 2¿¹(26.7%), Ç÷°ü ±ÙÀ° Áö¹æÁ¾°ú Àü¾Ï º´º¯ÀÌ °¢°¢ 2¿¹(13.3%)¿´°í, ÇÕº´³¶Á¾ÀÌ 1¿¹(6.7%)°üÂûµÇ¾ú´Ù. ¾Ç¼º Á¾¾ç°ú ¾ç¼º Á¾¾ç µÎ ±ºÀ¸·Î ³ª´©¾î ÀÓ»óÀû Ư¼º ¹× Á¶Á÷¼Ò°ßÀ» ºñ±³ÇÑ °á°ú, ¾Ç¼º Á¾¾ç±º¿¡¼­ À¯ÀÇÇÏ°Ô Åõ¼®±â°£(122.3¡¾61.8°³¿ù: 81.1¡¾56.7°³¿ù, p<0.05)ÀÌ ±æ¾ú°í, ÈÄõ¼º ½Å³¶Á¾(87.0%: 46.7%, p<0.01)À» µ¿¹ÝÇÑ °æ¿ì°¡ ÀǹÌÀÖ°Ô ¸¹¾Ò´Ù.

°á·Ð: ¸»±â ½ÅºÎÀüÁõÀ¸·Î Åõ¼®À» ¹Þ°í Àִ ȯÀÚ¿¡¼­ ½ÅÀûÃâ¼ú·Î È®ÀÎµÈ ½ÅÁ¾±«ÀÇ ´ëºÎºÐÀº ½Å¼¼Æ÷¾ÏÀ̾úÀ¸¸ç, ¾ç¼º Á¾¾ç¿¡ ºñÇØ ±ä Åõ¼® ±â°£°ú ÈÄõ¼º ½Å³¶Á¾ÀÇ µ¿¹Ý°ú ¿¬°üµÇ¾î ÀÖ¾ú´Ù.
Background/Aims: End-stage renal disease (ESRD) patients are at a higher risk for cancer, especially renal cell carcinoma (RCC). Acquired cystic kidney disease (ACKD) and long duration of dialysis predict RCC in these patients. We explored the clinical and pathologic characteristics of renal masses and the factors predicting malignant tumors.

Methods: The study examined the medical records of 38 ESRD patients who underwent partial/total nephrectomy due to renal masses diagnosed by abdominal ultrasound and computed tomography at YUHS from January 1995 to December 2009.

Results: Renal masses were recorded in 38 patients (21 males) with a mean age of 48.3¡¾13.2 years. Twenty patients (52.6%) were on hemodialysis and 18 patients (47.4%) were on peritoneal dialysis, for a mean period of 106.4¡¾62.5 months. ACKD was reported in 23 patients (67.6%). Of the 38 renal masses, 23 (60.5%) were diagnosed as malignant tumors and 15 (39.5%) were benign tumors. Clear cell RCC (n=16) and hematoma (n=6) was the predominant respective types. The patients with malignant tumors had a significantly longer duration of dialysis (122.3¡¾61.8 vs. 81.1¡¾56.7 months, p<0.05) and a higher prevalence of ACKD (87.0 vs. 46.7%, p<0.01) compared to the patients with benign tumors.

Conclusions: The most common renal mass in ESRD patients was RCC. Malignant tumors were significantly associated with a longer duration of dialysis and ACKD. Therefore, early evaluation and treatment of RCC are mandatory in long-term dialysis patients with ACKD.

Å°¿öµå

¸»±â ½ÅºÎÀüÁõ, Åõ¼®, ½ÅÁ¾±«, ½Å¼¼Æ÷¾Ï, ÈÄõ¼º ½Å³¶Á¾
End-stage renal disease, Dialysis, Renal mass, Renal cell carcinoma, Acquired cystic kidney disease
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
Malignant tumors were significantly associated with a longer duration of dialysis and Acquired cystic kidney disease (ACKD)
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå